Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RhuMab-E25 in Allergic Asthma
NCT00829179Phase 3Completed
- Sponsor
- Duke University
- Start
- Oct 2002
- Primary completion
- Jul 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in allergic asthma, sponsored by Duke University. Started Oct 2002; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00829179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00829179.